Oxford Biomedica (LSE: OXB)

Last close As at 20/12/2024

458.50

8.50 (1.89%)

Market capitalisation

GBP441m

Oxford Biomedica is a UK-based company with a leading position in cancer immunotherapy and gene-based products. It is focusing its efforts on two clinical programmes, ProSavin and TroVax, and has an ocular collaboration with Sanofi-Aventis.

Latest Insights

View More

Healthcare | Flash note

Oxford Biomedica — COVID vaccine and Kymriah news encouraging

Healthcare | edison tv

Oxford Biomedica: Edison Open House Healthcare 2022

Healthcare | edison tv

Oxford Biomedica – executive interview

Thematics

thematic

Healthcare

Healthcare-focused trusts: A sector on the mend

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free